@article{fdi:010089701,
  title = {{W}hat does the scale-up of long-acting {HIV} pre-exposure prophylaxis mean for the global hepatitis {B} epidemic ?},
  author = {{M}ohareb, {A}. {M}. and {K}ouam{\'e}, {M}. {G}. and {N}ouaman, {M}. and {K}im, {A}. {Y}. and {L}armarange, {J}oseph and {N}eilan, {A}. {M}. and {L}acombe, {K}. and {F}reedberg, {K}. {A}. and {B}oyd, {A}. and {C}offie, {P}. and {H}yle, {E}. {P}.},
  editor = {},
  language = {{ENG}},
  abstract = {{I}ntroduction: {T}he {HIV} and hepatitis {B} virus ({HBV}) epidemics are interconnected with shared routes of transmission and specific antiviral drugs that are effective against both viruses. {N}early, 300 million people around the world live with chronic {HBV}, many of whom are from priority populations who could benefit from {HIV} prevention services. {O}ral pre-exposure prophylaxis ({P}r{EP}) for {HIV} has implications in the prevention and treatment of {HBV} infection, but many people at increased risk of {HIV} acquisition may instead prefer long-acting formulations of {P}r{EP}, which are currently not active against {HBV}. {D}iscussion: {P}eople at increased risk for {HIV} acquisition may also be at risk for or already be living with {HBV} infection. {O}ral {P}r{EP} with tenofovir is effective in preventing both {HIV} and {HBV}, and tenofovir is also the recommended treatment for chronic {HBV} infection. {A}lthough implementation of oral {P}r{EP} has been challenging in sub-{S}aharan {A}frica, investments in its scale-up could secondarily reduce the clinical impact of {HBV}. {L}ong-acting {P}r{EP}, including injectable medicines and implantable rings, may overcome some of the implementation challenges associated with oral {P}r{EP}, such as daily pill burden, adherence challenges and stigma; however, current formulations of long-acting {P}r{EP} do not have activity against {HBV} replication. {I}deally, {P}r{EP} programmes would offer both oral and long-acting formulations with {HBV} screening to optimize {HIV} prevention services and {HBV} prevention and care, when appropriate. {P}eople who are not immune to {HBV} would benefit from being vaccinated against {HBV} before initiating long-acting {P}r{EP}. {P}eople who remain non-immune to {HBV} despite vaccination may benefit from being offered oral, tenofovir-based {P}r{EP} given its potential for {HBV} {P}r{EP}. {P}eople using {P}r{EP} and living with {HBV} who are not linked to dedicated {HBV} care would also benefit from laboratory monitoring at {P}r{EP} sites to ensure safety when using and after stopping tenofovir. {P}r{EP} programmes are ideal venues to offer {HBV} screening, {HBV} vaccination for people who are non-immune and treatment with tenofovir-based {P}r{EP} for people with indications for {HBV} therapy. {C}onclusions: {L}ong-acting {P}r{EP} holds promise for reducing {HIV} incidence, but its implications for the {HBV} epidemic, particularly in sub-{S}aharan {A}frica, should not be overlooked.},
  keywords = {cabotegravir ; hepatitis {B} ; hepatitis ; {HIV} ; long-acting antiretroviral ; therapy ; long-acting {P}r{EP} ; {P}r{EP} ; tenofovir ; {MONDE}},
  booktitle = {},
  journal = {{J}ournal of the {I}nternational {AIDS} {S}ociety},
  volume = {27},
  numero = {3},
  pages = {e26218 [6 ]},
  year = {2024},
  DOI = {10.1002/jia2.26218},
  URL = {https://www.documentation.ird.fr/hor/fdi:010089701},
}